duction in the incidence and/or severity of chronic postmastectomy pain. In addition, we did not detect a dose-response effect of dexamethasone on the incidence of chronic postsurgical pain. T he development of chronic pain after surgery can be common for specific surgical procedures such as thoracic, inguinal hernia repair, and mastectomy. [1] [2] [3] In breast cancer surgery, the incidence of chronic pain has been reported to be 40% to 50%. 4 Causal mechanisms for the development of chronic postsurgical pain are largely unknown, but the role of the perioperative inflammatory response has been repeatedly mentioned as a possible contributing factor and a possible preventive pharmacological target. [5] [6] [7] [8] [9] Dexamethasone is a glucorticosteroid with potent antiinflammatory properties. 10 Dexamethasone is used perioperatively to reduce postoperative nausea and pain and to improve quality of recovery. [11] [12] [13] [14] Among common perioperative drugs, dexamethasone seems to be a very viable strategy to minimize perioperative inflammation and subsequently reduce the development of chronic postsurgical pain. However, it is currently unknown if the use of perioperative dexamethasone is associated with a lower incidence and severity of chronic pain after surgery.
The main objective of the current investigation was to evaluate a possible association between administration of intravenous dexamethasone 4 to 20 mg on the day of surgery with self-reported breast or axillary pain at a minimum of 3 months following mastectomy. We hypothesized that patients receiving perioperative dexamethasone would have a lower incidence or reduced severity of chronic postmastectomy pain.
METHODS
The study was a single-center observation cohort study. The results presented in this article represent a secondary analysis of data collected for evaluation of risk factors in the development of chronic pain following mastectomy. 15, 16 Study approval was granted by the institutional review board of Northwestern University, STU00061993 approved April 2012. Subjects were patients of the Lynn Sage Breast Cancer Center at Prentice Women's Hospital of Northwestern University, a tertiary care women's hospital. The center performs approximately 600 surgeries for breast cancer annually. Patients with breast cancer who had mastectomy with or without lymph node dissection and/or reconstruction from January 2008 through August 2013 were identified, and eligible subjects approached at follow-up visits at least 3 months following their last surgical procedure (including breast reconstruction procedures). Written informed consent was obtained from all participant subjects. Patients who were not fluent in English, who reported a prior history of chronic pain (>3 months) in the breast or axillary area before surgery, women with a history of other chronic pain conditions, or those requiring opioid analgesics prior to surgery were excluded.
Participating subjects responded to face-to-face questionnaires administered by a member of the study team (J.M.B.). Subjects were asked to respond to the modified short-form Brief Pain Inventory (BPI) and the short-form McGill Pain Questionnaire to identify and characterize pain. 17, 18 The following data were also obtained from patients and/or electronic medical records: demographic characteristics (age, height, and weight), preoperative medications, history of preoperative psychiatric disease (depression and /or anxiety), history of preoperative chronic pain in a different body region (osteoarthritis, back pain, migraines), surgical procedure, surgical duration, surgeon performing the procedure, surgical procedure on axilla, tumor staging, presence of breast reconstruction, postoperative opioid consumption, presence, type and number of cycles of chemotherapy, use of radiation treatment, and use and dose of dexamethasone on the day of surgery, as well as during chemotherapy cycles between the day of surgery and follow-up evaluation. The data were entered (J.M.B.) to a research database (PostgreSql version 9.4.1) maintained by the Department of Anesthesiology at Northwestern University that has been previously used to assess the development of chronic pain after breast reconstructive surgery. 14, 15 Data verification (by R.J.M.) was performed by comparison with source documents.
The primary outcome was the presence of chronic pain in the breast and/or axillae after the surgical procedure in patients who had mastectomy with and without breast reconstruction. Chronic postmastectomy pain was defined in accordance with the IMMPACT (Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials) recommendations: (1) pain in the area of the surgery, (2) pain duration of at least 3 months, and (3) average daily pain intensity of at least 4 on a 0-to 10-point scale. 19 Subjects with a history of psychiatric illness were included in the analysis, because the negative effects of depression and anxiety are likely offset by the beneficial effects of treatment.
The study groups were formed based on subjects who received intraoperative intravenous dexamethasone and subjects who did not receive intraoperative dexamethasone. Assuming a 50% incidence of chronic pain, it would require 247, 59, and 23 subjects per group in order to achieve 80% power to detect a 25%, 50%, and 75% relative reduction in the incidence of chronic pain in the perioperative dexamethasone group compared with the no-dexamethasone group using a 2-tailed α set at 0.05. Similar effect sizes have been reported by other perioperative interventions.
20,21

Statistical Analysis
Interval and ordinal data are reported as median (range or interquartile range) and compared between groups using the Mann-Whitney U test. 22, 23 Categorical data are presented as counts (percentages), and univariate associations were performed by constructing cross tabulations and compared between groups using Fisher exact test. Confidence intervals of incidences and differences in incidences were calculated using the Clopper-Pearson FIGURE 1. CONSORT diagram of subject study participation. method. Missing data were excluded from analysis on a casewise basis.
Variables with a univariate P < 0.1 were entered in a recursive nonparametric classification tree analysis based on χ 2 automatic interaction detection. This analysis determines optimal cutoff values for continuous variables associated with the risk of developing chronic postmastectomy pain. Significant variables identified at the terminal branches by classification analysis as well as the use of intraoperative dexamethasone were then entered into a binary logistic regression model to determine the risk-adjusted odds ratio for developemnt of postmastectomy chronic pain. Accuracy or the logistic regression model was evaluated by the area under the receiver operating characteristic curve c-statistic and 95% confidence interval (CI). Stratification analysis was performed to examine an association between the use of postsurgical dexamethasone and the outcomes. Data analysis was performed 
RESULTS
Three hundred ten patients were included in the study. The details of subject participation are shown in Figure 1 . The median (interquartile range) time from last surgery to subject's evaluation was 17 (8/27) months. Fifty-two patients (17%) met the IMMPACT criteria for chronic pain in the breast and/or axillary region. Data on preoperative clinical demographics, tumor pathology, surgical findings, 24-hour postoperative pain and analgesic requirements, chemotherapy, and radiation in subjects with and without chronic postmastectomy pain are shown in Table 1 . Baseline unadjusted surgical and patient characteristics were significantly different in regard to age, body mass index, pain in other locations, lymph node dissection, and TNM cancer stage.
A comparison of the BPI in subjects with and without chronic postmastectomy pain is shown in Table 2 (Supplemental Digital Content 1, http://links.lww.com/AAP/A150). Worst pain intensity, current pain, and pain interference with activities of daily life were significantly greater in subjects with chronic postmastectomy pain. Similarly, the scores for the pain descriptors in the McGill short form demonstrated greater severity of pain in subjects with chronic postmastectomy pain ( Table 3 , Supplemental Digital Content 1, http://links.lww. com/AAP/A150).
The incidence of chronic pain in the mastectomy group who received perioperative dexamethasone was not significantly different, 15 (15.2%) of 84 compared with 37 (17.5%) of 211 in the group who did not receive perioperative dexamethasone, difference −2% (95% CI, −10 to 7; P = 0.75). The median dose of perioperative dexamethasone was 8 mg (range, 4-20 mg). Increasing dexamethasone was not associated with a decrease in the incidence of chronic postmastectomy pain, ρ = −0.31, P = 0.65. When stratified by postdischarge dexamethasone administration, the incidence of chronic postmastectomy pain in the group that did not receive dexamethasone was 12% (95% CI, 5%-24%), 18% (95% CI, 12%-28%) in the group that received perioperative dexamethasone only, 18% (95% CI, 10%-32%) in the group that received dexamethasone during postoperative chemotherapy cycles only, and 17% (95% CI, 10%-25%) in subjects who received post-perioperative and postsurgical dexamethasone during chemotherapy cycles (P = 0.78).
Classification tree analysis identified lymph node dissection and duration of surgery at a cutoff value of 236 minutes as independent risk factors for the development of chronic postmastectomy pain (Fig. 2) . The frequency of lymph node dissection was similar in subjects who received perioperative dexamethasone, 28% (95% CI, 23%-35%), and those who did not receive perioperative dexamethasone, 28% (95% CI, 20%-39%) (P = 0.95). Median surgical duration was longer in subjects who received perioperative dexamethasone, 207 minutes (95% CI, 138-264 minutes), compared with those who did not receive perioperative dexamethasone, 156 minutes (95% CI, 108-228 minutes) (P = 0.03).
Binary logistic regression demonstrated an odds ratio for the development of chronic postmastectomy pain in subjects without lymph node dissection with a surgical duration greater than 236 minutes was 4.4 (95% CI, 1.9-10.3; P < 0.0005) compared with subjects without lymph node dissection and a surgical duration of less than or equal to 236 minutes. Subjects with lymph node dissection had an odds of developing chronic postmastectomy pain of 5.0 (95% CI, 2.3-10.8; P < 0.0005) compared with subjects without lymph node dissection and a surgical duration of less than 236 minutes. The risk-adjusted odds ratio for development of chronic postmastectomy pain in subjects receiving perioperative dexamethasone was 1.0 (95% CI, 0.51-2.0; P = 0.97). The c-statistic for the model was 0.68 (95% CI, 0.61-0.76).
There were no differences between the study groups in the BPI questionnaire responses for worst pain severity (P = 0.48), average daily pain severity (P = 0.73), current pain severity (P = 0.30), pain relief with analgesics P = 0.1), pain interference with daily activities (P = 0.37), pain interference with normal work (P = 0.57), pain interference with relationships (P = 0.81), or the National Depression Screening Day score (P = 0.81). Subjects who received perioperative dexamethasone reported increased frequency of greater severity responses to the sharp (P = 0.03), aching (P = 0.02), and heavy (P = 0.04) pain descriptors on the McGill Pain Questionnaire short form, whereas subjects who did not receive perioperative dexamethasone report an increased frequency in the cramping pain descriptor (P = 0.03).
DISCUSSION
The most important finding of the current investigation was the lack of association between perioperative dexamethasone administration and a reduced incidence of chronic postmastectomy pain. The association was not present even for greater perioperative doses of dexamethasone. In addition, the severity of chronic pain after mastectomy as assessed by the BPI was not different in patients who received perioperative dexamethasone compared with patients who did not receive perioperative dexamethasone. Contrary to what we hypothesized, our results do not support the use of perioperative dexamethasone to decrease the incidence/ severity of chronic pain after mastectomy.
Our results are important because it significantly differs from current studies that support the use of short perioperative interventions as a significant strategy to reduce chronic postsurgical pain. Grigoras et al 24 have observed a very large effect (>35% reduction) on the incidence of chronic pain after mastectomy by a short perioperative infusion of systemic lidocaine. Cho et al 4 found a 50% greater incidence of chronic pain in patients who received propofol for anesthetic maintenance compared with patients who received sevoflurane. However, those findings have been criticized by other investigators. 25 Systemic dexamethasone has been shown to reduce central and peripheral inflammation in chronic pain states. 26, 27 The immune system has recently gained a notorious role in mechanisms leading to the development of chronic pain. 28 In addition to peripheral sensitization, inflammation of the central nervous system occurs when peripheral tissue inflammation or nerve injury occurs. Despite our current findings, it seems that among all clinical perioperative interventions, dexamethasone has a promising biologic basis to prevent the development of chronic postsurgical pain.
Immunosuppresion during the perioperative period has been implicated with the development of early recurrences in cancer patients. 29, 30 The effects of dexamethasone on the immune system and its implications on breast cancer recurrence are currently unknown. It is therefore possible that clinical practitioners avoid dexamethasone in cancer patients to minimize perioperative immunosuppression. Nevertheless, dexamethasone was not associated with adverse clinical outcomes in endometrial and ovarian cancer patients. 31, 32 Romundstad and colleagues 33 evaluated the effect of a preoperative dose of methylprednisolone compared with placebo on the incidence of chronic pain and long-term sensory changes after cosmetic augmentation mammoplasty. The authors detected a reduction in hyperesthesia in patients who received methylprednisolone but did not detect an effect of methylprednisolone on the incidence of persistent spontaneous or evoked pain. Our current results support the prior findings of Romundstad and colleagues. 33 Our study should be interpreted only in the context of its limitations. There was no standardization of perioperative anesthetic and analgesic regimens, which precluded us from examining the relationship between a preventive analgesic effect of dexamethasone and its relation with the development of chronic pain. The incidence of postmastectomy pain reported in this study, 17%, is significantly lower than the incidence (~50%) reported in prior studies of postmastectomy pain. 4, 15, 16 This difference is primarily a result of the use of the IMMPACT guidelines for the determination of chronic pain. 19 Nevertheless, it is possible that, given study bias and limitations, a preventive effect for some patient subsets has been missed, perhaps on intensity or characteristics of the chronic pain.
Breast surgery can induce pain with neuropathic characteristics. In order to minimize questionnaire burden of participants, we did not use an additional questionnaire specifically designed to evaluate neuropathic pain. 34 Because the use of the McGill Pain Questionnaire is not optimal to characterize neuropathic pain, future studies should include a specific and validated questionnaire to examine neuropathic pain in patients after breast surgery.
Although we used multivariate methods to control to adjust for the effects of covariate bias in the primary outcome, we cannot rule out the presence of residual confounding bias in observational analysis. We have evaluated with respect to perioperative dexamethasone exposure, because prior studies demonstrating preemptive effects of pharmacologic interventions following require exposure at the time surgery. Because dexamethasone is frequently administered with chemotherapy, many subjects received dexamethasone in the postsurgical period, although no difference in chronic postmastectomy pain was observed when stratified by postsurgical dexamethasone administration. Although our observational evaluation does not support a beneficial effect of perioperative dexamethasone, only a large randomized controlled trial can definitively rule out a beneficial role of perioperative dexamethasone on chronic postmastectomy pain.
In summary, we did not detect an association between the use of perioperative dexamethasone and the development of chronic pain after mastectomy. Our study does not support the use of perioperative dexamethasone to prevent chronic postsurgical pain. More studies are likely needed before establishing the efficacy of short perioperative interventions to prevent the development of chronic postsurgical pain.
